Statin Use Attenuates Leuprolide-Associated Coronary Atherosclerosis Progression
Authors:
- Adithya K. YadalamAYAdithya K. Yadalam
- Chang LiuCLChang Liu
- Marly van AssenMAMarly van Assen
- Nikhil T. SebastianNSNikhil T. Sebastian
- Vishal R. DhereVDVishal R. Dhere
- Bruce W. HershatterBHBruce W. Hershatter
- Pretesh R. PatelPPPretesh R. Patel
- Ashesh B. JaniAJAshesh B. Jani
- Carlo N. De CeccoCCCarlo N. De Cecco
- Stephanie M. CantuSCStephanie M. Cantu
- Anant MandawatAMAnant Mandawat
- Sagar A. PatelSPSagar A. Patel
Open Access
- 18 August 2026
- journal article
- Published by Elsevier in JACC: Cardiooncology
- Vol. 8 (4) , 440-442
Abstract
No abstract availableFunding Information
- Pfizer
- National Comprehensive Cancer Network
- National Heart, Lung, and Blood Institute
- Siemens Medical Solutions USA
- Prostate Cancer Foundation
- National Cancer Institute
This publication has 5 references indexed in Scilit:
- Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate CancerJAMA Cardiology, 2026
- Cardiovascular Risk in Prostate CancerJACC: Cardiooncology, 2024
- Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancerJournal of the American Pharmacists Association, 2022
- Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque CompositionJAMA Cardiology, 2021
- Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate CancerNew England Journal of Medicine, 2020